Capricor Therapeutics is a San Diego-based clinical-stage biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, with the lead asset Deramiocel in late-stage development for Duchenne muscular dystrophy cardiomyopathy, and the company is in the middle of a fiscal second quarter that demonstrates the kind of FDA-review pivot the cell-therapy biotech cohort has been watching with extraordinary interest. Q2 2026 net loss of $40.7 million, or $0.70 per share, was 57.1 percent above the prior-year quarter's $25.9 million, the H1 2026 net loss of $74.7 million was 48.4 percent above the prior-year period's $50.3 million, and the cash position of $237.9 million at quarter-end is the cleanest single-sentence read on the financial position the company is producing. The combination of the FDA review of the Deramiocel BLA, the HOPE-3 Phase 3 results published in The Lancet, and the cash runway through the regulatory decision is the cleanest single read on what the cell-therapy biotech business model is producing, and the combination is the source of the platform-validation profile the equity offers the buy-side.
The numbers tell the story with the kind of operational detail the cell-therapy biotech equity has been waiting for. The Q2 2026 R&D expense of $28.9 million was 30.9 percent above the prior-year quarter's $22.0 million, and the H1 2026 R&D expense of $56.2 million was 37.3 percent above the prior-year period's $41.0 million. The G&A expense of $14.1 million in the quarter was 148.4 percent above the prior-year quarter's $5.7 million, and the H1 2026 G&A expense of $23.5 million was 100.0 percent above the prior-year period's $11.7 million. The total operating expenses of $42.9 million in the quarter were 55.0 percent above the prior-year quarter's $27.7 million.
The investment income of $2.2 million in the quarter was 23.3 percent above the prior-year quarter's $1.8 million, with the investment income growth reflecting the cash and marketable securities balance the company is holding. The cash, cash equivalents and marketable securities position declined from $318.1 million at year-end 2025 to $237.9 million at quarter-end, with the cash decline of $80.2 million during the H1 2026 driven by the operating cash burn the company is producing.
The question the next four quarters resolve is whether the FDA approves the Deramiocel BLA or issues a complete response letter, and whether the company is positioned to launch Deramiocel commercially if the BLA is approved. A Q3 2026 or Q4 2026 update that announces the FDA approval of the Deramiocel BLA would confirm the platform-validation profile is producing, with the resulting commercial launch positioning the company as a Duchenne muscular dystrophy cardiomyopathy commercial entity. A Q3 2026 or Q4 2026 update that announces a complete response letter would force the market to reprice the equity for a more modest terminal value, with the company returning to a clinical-development trajectory.